Vaishali Pharma credit ratios

·UnclassifiedChart ›

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023

18.5	18.5	11.7	12.6	13.7
17.1	17.1	9.8	11.0	12.7
0.27×	0.27×	0.18×	0.29×	0.34×
0.25×	0.25×	0.15×	0.26×	0.31×
4.50×	4.50×	—	—	—
4.04×	4.16×	—	—	—
1.79×	1.79×	—	—	—
21.1%	21.1%	15.2%	22.7%	25.2%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

VAISHALI₹6.87

Vaishali Pharma Limited

· Unclassified

₹ CrorePeersTEMBO TOTAL OSWALSEEDS GROBTEA BEARDSELL HINDCON CROWN ARTNIRMANMcap ₹44.8 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Total Debt	13.7	12.6	11.7	18.5	18.5
Net Debt	12.7	11.0	9.8	17.1	17.1
Total Debt/Equity	0.34	0.29	0.18	0.27	0.27
Net Debt/Equity	0.31	0.26	0.15	0.25	0.25
Total Debt/EBITDA	—	—	—	4.50	4.50
Net Debt/EBITDA	—	—	—	4.16	4.04
Interest Coverage (EBIT/Interest)	—	—	—	1.79	1.79
Total Debt/Total Capital %	25.21	22.74	15.23	21.14	21.14

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.